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Summary 
T cells appear to play a central role in viral bronchiolitis, but the effects of different functional 
and phenotypic subgroups ofT cells have not been defined. To test the activities ofT cells recognizing 
individual proteins of respiratory syncytial (RS) virus, virus-specific T  cell lines were produced 
from mice primed by scarification with recombinant vaccinia viruses expressing the major surface 
glycoprotein (G), fusion protein (F) or second matrix (22K) protein of KS virus. As previously 
reported, the in vitro characteristics of these cells are predetermined by the choice of KS virus 
protein:  22K-specific  cells are predominantly class I-restricted cytolytic CD8 + cells;  F-specific 
cells, a mixture of cytolytic CD8 + cells and CD4 + cells with a T  helper 1 cell (Thl) cytokine 
secretion profile, whereas those from G-sensitized mice are almost exclusively CD4 + , with Th2 
characteristics. Mice infected intranasally with RS virus showed mild illness and recovered fully, 
but developed respiratory distress after intravenous injections of T cells. Dose-for-dose, infected 
mice receiving G-specific  cells suffered the most severe (sometimes fatal)  illness,  characterized 
by lung hemorrhage, pulmonary neutrophil recruitment (shock lung) and intense pulmonary 
eosinophilia. This disease was further enhanced by coinjection of 22K-specific cells, which alone 
caused mild shock lung without eosinophilia. F-specific cells caused minimal enhancement of 
pathology and had little or no effect on the disease caused by G-specific cells. Each cell line reduced 
lung virus titer and combined injections of G- and 22K-specific cells eliminated infection completely. 
The in vitro characteristics of these antiviral T cell lines therefore predict the pathological effects 
in vivo.  Moreover, different forms of viral bronchiolitis can be caused by functionally distinct 
types of activated T  cell. 
V 
iral bronchiolitis is the single most common cause of 
hospitalization of infants in the Western world, but the 
development of effective preventative or therapeutic stratagems 
has been hampered by lack of information about its patho- 
genesis.  The majority of cases are caused by respiratory syn- 
cytial (R,S)* virus, the annual hospitalization costs of which 
were estimated to be $300,000,000  in  1988 in the United 
States alone, with 91,000 children admitted (1). Antiviral im- 
munity appears not only to protect against infection but also 
to contribute to lung pathology. The first evidence that specific 
immunity could be harmful came in the 1960s, when chil- 
dren were vaccinated with formalin-inactivated RS virus. Vac- 
cine recipients developed strong serological responses, but were 
not protected against infection. Moreover, the majority of 
vaccinees who subsequently became infected with RS virus 
developed severe lower respiratory tract disease, with significant 
mortality. The reasons for vaccine-augmented disease  have 
1 Abbreviations used in this paper: BAL, bronchoalveolar  lavage; CS, culture 
supernatant; F, fusion  protein; G, major  surface  glycoprotein;  RS, respiratory 
syncytial; rVV, recombinant  vaccinia virus; 22K, 22kDa second matrix 
protein of KS virus. 
been studied (2-5), but no safe, effective vaccine has yet been 
produced. 
Animal studies suggest that specific activated T  cells are 
probably responsible for this phenomenon of disease augmen- 
tation, and may also be responsible for many of the patho- 
logical effects seen during primary and secondary RS virus 
infections. Passive transfer of specific antiviral Ab does not 
enhance disease, either protecting against infection and dis- 
ease or being neutral in effect. Mice infected with RS virus 
develop a lymphocytosis in the hronchoalveolar lavage (BAL) 
fluid, dominated by CD8 + c~/3 T cells at the time of virus 
elimination (6).  Treatment of such mice by injection of T 
cell-depleting anti-CD4 and/or anti-CD8 mAbs reduces or 
abolishes disease, while enhancing virus replication (7). Adop- 
tive transfer of CD8 § CTL lines or clones can eliminate in- 
fection in vivo, while also causing hemorrhagic, neutrophilic, 
and sometimes fatal pneumonitis (8).  CD4 + Th cells also 
have distinct antiviral and pathogenic effects, and may be more 
potent on a cell-for-cell basis than CD8 + T cells (9). During 
reinfection, both T cell subsets have to be depleted to com- 
pletely abolish the enhanced pathological response (7). Cotton 
rats vaccinated with formalin-inactivated KS virus (3, 10, 11) 
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encoding some single proteins of RS virus (12,  13) show a 
reduction in lung virus titer after challenge with R.S virus. 
In both these situations,  there can also be a paradoxical in- 
crease in the severity of lung pathology  (3,  5,  10,  11,  14, 
15).  In mice given formalin-inactivated KS virus intramus- 
cularly, vaccine-enhanced disease is abolished by CD4 + cell 
depletion in vivo but is little affected by depletion of CD8 + 
cells (4). The immune mechanisms responsible for enhanced 
disease in mice primed with recombinant vaccinia viruses have 
not been  defined. 
In KS virus-infected mice previously sensitized with rVV- 
expressing individual RS virus proteins, BAL has shown the 
patterns of immunopathology to vary depending on the RS 
virus protein to which the mice are sensitized. Remarkably, 
mice sensitized to the major surface glycoprotein (G) develop 
RS virus-specific Th cells which release IL-4 and IL-5 in re- 
sponse to antigen  (16),  and after infectious challenge with 
RS virus,  suffer disease characterized by a striking increase 
in BAL eosinophils (14-25%,  from <3%  in controls) (15). 
Recently, virus-specific T  cell lines were derived from mice 
primed by scarification with rVV-expressing single RS virus 
proteins (17). For the present studies, we selected three cell 
lines as being of special interest: the G-specific line, because 
it is dominated by CD4 §  T  cells with Th2 characteristics; 
the  fusion  protein  (F)-specific  line,  because  it  contains 
CD4 §  cells with  Thl  characteristics,  as well as class  I-re- 
stricted CTL; and the 22K-specific line, because it is domi- 
nated by CTL alone. Immune responses to these three pro- 
teins are also of special interest in terms of vaccine development. 
F  and G  are the main  surface glycoproteins against  which 
Ab responses occur, and 22K is the main target for CTL in 
the mouse. We now report the in vivo effects of T  cell lines 
specific to these three KS virus proteins, and show that these 
T  cells can transfer the antiviral and pathogenic effects seen 
in mice sensitized to single viral proteins to naive syngeneic 
recipients. 
Materials and Methods 
Viruses and Mice 
The human A2 strain of RS virus was grown and assayed for 
infectivity in HEp2 cells, as previously described (9). Mock-infected 
HEp2 cells were treated in the same way to derive control antigen. 
Infectious units of RS virus (i.e., each of which is able to induce 
a single immunoperoxidase-positive cell) were regarded as equiva- 
lent to PFU. All rVV were the kind gifts of Drs. Wertz, Ball, and 
Anderson (University of Alabama, Birmingham, AL) and were pro- 
duced by insertion of the cDNA transcript of the RNA sequence 
for a specific protein from the A2 strain of RS virus according to 
the protocol described by Ball et al. (18). All rVV were grown in 
HEp2 cells, and infectivity was measured by plaque assay in 24-well 
plates (Costar Corp., Cambridge, MA). Recombinant VV-F (VF 
317), G (VAG 301), and 22K have been described previously (12, 
13,  19). Similar rVV expressing 3Gal was used as a control. All 
virus stocks and cells were free of mycoplasma infection by DNA 
hybridization (Gen-probe Inc., San Diego, CA). AUantoic fluid con- 
taining influenza A X31 (H3N2) was provided by Dr. A. Douglas 
(National Institute for Medical Research, Mill Hill, London, UK) 
at 4,096 hemagglutination units  (HAU) m1-1.  Female  BALB/c 
mice 3-4-mo-old (Harlan Olac, Bicester, Oxon, UK) were infected 
intranasally with 2  ￿  105 PFU of RS virus, 7 HALT of influenza, 
or scarified over the rump and tail base with rVV stock diluted 
to contain 3  ￿  10  ~ PFU in 10/~l/mouse (19). rVV-infected mice 
were checked for formation of typical infective lesions on days 3 to 5. 
T  Cell Lines 
Spleen cells from primed mice were suspended  at 106 cells/ml 
with 2.5  ￿  10  s cells/ml RS virus-infected autologous splenocytes 
(stimulator  cells)  at  a  multiplicity of infection (m.o.i.)  of 0.1 
PFU/cell, in 15 ml RPMI 1640 medium (GIBCO BILL, Paisley, 
Scotland) supplemented with 10%  FCS,  antibiotics,  2-ME, and 
glutamine (RPMI/10). After 5 d, cells were washed and suspended 
at 2  ￿  10  s cells/ml with normal syngeneic irradiated spleen cells 
(2  ￿  106 cells/ml).  After 5-6  d  of antigenic "rest," cells were 
washed and stimulated with antigen presented by normal syngeneic 
irradiated cells infected with KS virus at similar cell densities. This 
stimulation/rest cycle was repeated up to seven times. It was neces- 
sary to add 5% Con A-stimulated rat spleen cell culture superna- 
tant (Con A supernatant) to the predominantly CD8 + T cell line 
derived from mice primed with rVV-22K after the second cycle, 
in order to maintain growth (see Results).  As controls, spleen cells 
from unprimed  mice and  mice inoculated  with  rVV-~Gal  (by 
scarification) or HEp2 cell material (transnasally)  were cultured as 
described for RS virus-specific T cell lines. Cell transfers were per- 
formed by tail vein injection within 4 h  of intranasal  challenge. 
Fluorescent Staining for Lymphocyte Surface Markers 
For three-color analysis, cell pellets  were incubated first with 
Abs to TCR-c~/~ (af~nity purified H57-597 at a final concentra- 
tion of 1.15/~g/ml), TCR-C3, (Uc7-13D5 bioreactor supernatant 
kindly given by Dr. J. Bluestone (University of Chicago, Chicago, 
IL), used at 1 in 100), CD3 (145-2cll supernatant, final concen- 
tration 1 in 100), CD45RB (16A, rat mAb kindly given by Dr. 
K. Bottomly (Yale University, New Haven, CT), final concentra- 
tion 1 in 1,000), or left without first layer Ab. Bound Ig was de- 
tected by FITC-conjugated goat anti-hamster Ab (Cappel Organon 
Teknika Corp., West Chester, PA) which also reacts with rat Ig. 
After blocking with 1 mg/ml a~nity-purified rat Ig (Sigma Chem- 
ical Co., St. Louis, MO), appropriate dilutions of coupled Ab to 
CD4 (GK 1.5-PE; Becton Dickinson & Co., Mountain View, CA) 
and CD8 (53-6.7-biotin, Becton Dickinson & Co.) were added; 
the CD8 stain was developed with streptavidin-duochrome (Becton 
Dickinson & Co.). For two-color stains, appropriate dilutions of 
GK 1.5-PE and 53-6.7-FITC (Becton Dickinson & Co.) were used. 
All procedures were performed on ice with 0.1% sodium azide and 
1%  BSA.  Cells  were analyzed on a FACScan  |  flow cytometer 
(Becton Dickinson & Co.). 
Cytotoxicity Assay 
P815 cells were infected overnight with RS virus at an moi of 
2 PFU/cell or rVV at 10 PFU/cell. Uninfected or rVV-~Gal-in- 
fected P815 cells served as control targets. A chromium release assay 
was performed as previously described  (19). Briefly, targets were 
labeled with Na2SlCrO4 for 50 rain at 37~  washed, and diluted 
to 105/ml.  Effector cells were mixed with targets and incubated 
for 3 h in 96-well plates. The percent lysis was calculated by meas- 
uring 51Cr release into the supernatant:  100x  [(sample cpm  - 
background cpm)/(total cpm  -  background cpm)], where total 
cpm is the radioactivity released from targets treated with Triton 
X-100. 
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Cell lines were cultured with irradiated  syngeneic spleen cells 
that were either uninfected or infected with the RS virus. Culture 
supernatants (CS) were tested for cytokines on day 1 to 3 after an- 
tigenic stimulation. 
IL2 Assay.  IL-2 dependent CT.EV cells (20) were maintained 
in RPMI/10 and 5% IL-2 (CS of X6310 line expressing  mRNA 
for II.-2 [21]). These were washed four times and suspended at 10  s 
cells/ml.  5  x  103 cells were incubated with  50/~1  of each test 
sample in 96-well round-bottomed microtiter plates for 42 h be- 
fore addition of 0.5 #Ci/well  of [3H]TdR for 6 h.  The cellular 
DNA was harvested onto filters, dried,  and assayed by liquid scin- 
tillation counting. The results  were calculated  as the mean cpm 
of triplicates  after subtraction of counts obtained when cells were 
incubated with medium alone  (typically 200-400 cpm). In each 
assay, wells containing rIL-2 acted as positive controls. Selected CS 
were also tested  in the presence or absence of 11Bll anti-IL-4 or 
$4B6 anti-IL-2 monoclonals, which confirmed that the action on 
CT.EV cells could be fully ascribed to II.-2. Alternatively,  CTLL 
cells were used  to measure  IL-2/4 levels. In this  case, cells were 
pulsed  with [3H]TdR at 18-24 h, and inhibition of proliferation 
by anti-IL-2 was used  to identify stimulation caused by IL-2. In 
the presence  of anti-IL-2,  residual  proliferation  is caused by IL-4 
and is fully inhibitable  by anti-IL-4 (see below). Although multiple 
dilutions and time intervals up to day 4 were tested, here we report 
the results  of assays on 1:2 dilutions of CS collected on day 1 or 
2,  as optimal levels were found at  this  time.  Essentially  similar 
methods were used to measure IL-3, -4, and -5, with the following 
modifications. 
IL3 Assay.  The B13 cell line (LyH7-B13) was maintained  with 
10 U/ml rIL-5 (CS of X6310 cell line expressing  mRNA for IL-5 
[21]). This line responds to both IL-5 and IL-3, and in the presence 
of anti-IL-5 Ab (TRFK.5 hybridoma CS at 1:20 dilution [22]), be- 
haves in an IL-3-responsive manner. Under these conditions, prolifer- 
ation is proportional to that of IL-3-responsive  32D cells (16 and 
our unpublished results). 
1114 Assay.  IL-4 dependent cell line CT.4S (20) was maintained 
in medium supplemented with 5% rIL-4 (CS of X6310 cell line 
expressing  mRNA for IL-4 [21]). Results from this assay are con- 
cordant with results  obtained from CTLL cells stimulated by CS 
in the presence  of anti-IL-2 Ab (see above). 
11-.5 Assay.  B13 cells were maintained with rIL-5 produced from 
transfected  X6310 cells as  above. The proliferation  inhibited by 
TRFK.5 Ab was taken  to represent  IL-5 activity (16). Residual 
proliferation in the presence of anti-IL-5 is probably caused by IL-3 
(see above). 
In  Vivo  Testing of Celt Lines 
The cell lines were injected into mice intravenously within 4 h 
of intranasal  infection. Mice were inspected  daily for signs of ill- 
ness, and weighed before and at intervals after challenge as a quan- 
titative  index of disease. All surviving mice were killed  on day 4 
and  subjected  to BAL,  and lungs were  homogenized for virus 
titration. 
In experiment 1, 13 mice were infected with KS virus and an- 
other 12 were given control material intranasally  (mock infection). 
Of the RS virus-infected mice,  four were injected  intravenously 
with 3  x  106 G-specific cells, two with similar numbers of 22K- 
specific cells, and four with both cell lines (total,  6  x  106 cells). 
Of the mock-infected mice,  four were injected  with G- and four 
with 22K-specific cells. The remaining mice were left as controls. 
All cells were injected 3 d after the third cycle of antigen stimula- 
tion in vitro. 
In experiment 2, 24 mice were infected  intranasally  with RS 
virus,  8 with influenza  A, and 4 with mock antigen. Of the RS 
virus-infected mice,  four were injected  with 3  x  106 G-specific 
cells, four with a mixture of G and 22K cells at a 3:1 ratio (total, 
4  x  106 cells), four with a 3:3 mixture (total,  6  x  106), four with 
a 1:3 mixture, and four with 3  x  106 22K-specific cells alone. All 
the mock-infected mice, four of the eight influenza-infected,  and 
four uninfected mice were injected with a 3:3 mixture of  cells. The 
remaining virus-infected  mice were left as controls, without injec- 
tion. In this experiment, all cells were injected  3 d after the fifth 
cycle of antigen stimulation in vitro. 
In experiment 3, the in vivo effects ofF- and G-specific cell lines 
were compared on day 3 after the third cycle of antigen stimula- 
tion.  Groups of mice were infected  intranasally  with  RS virus 
(n  =  15), influenza  (n  =  6), given mock HEp2 antigen (n  =  6), 
or left uninoculated (n  =  3). Of the KS virus-infected mice, four 
were  given 3  x  106 F-specific cells,  a further  four were given 
3  x  10  e G-specific cells, and four given both G- and F-specific cells 
(total,  6  x  106 cells per mouse). The remaining three mice were 
left without cell transfers.  Half of the influenza  or mock-infected 
mice were injected with both G- and F-specific cells, which were 
also injected  into all three uninoculated mice. 
Bronckoalveolar Lavage 
Mice were given 3 mg pentobarbitone intraperitoneally and ex- 
sanguinated via the femoral vessels. The thorax was opened, and 
1.2 mm portex tubing introduced into the trachea at the cricothyroid 
membrane.  1 ml of 12 mM lignocaine  in PBS was washed in and 
out six times over a 1-2-min period to promote elution of adherent 
cells.  2 ml of hemolytic HBSS was added  to the cell suspension 
for 5 rain, and 150 #1 was removed for spectrophotometric estima- 
tion of hemoglobin content (8). The remaining cells were washed 
and cytocentrifuge preparations made, which were fixed and stained 
with Giemsa's reagent. 300-500 cells per slide were identified  and 
counted by oil immersion light microscopy. 
Virus  Titration in the Lung  Tissues 
After BAL, both lungs from each mouse were homogenized to- 
gether in 1 ml of virus stabilization  buffer as previously described 
(8). Homogenates were centrifuged at 10,000 g for 1 min and su- 
pernatants stored in liquid nitrogen before determination of virus 
titer in HEp2 cells were cultured in square, flat-bottomed 25-well 
plates.  Wells were infected with dilutions of standards  or homo- 
genates in 500 #l/well of PBS for 1.5 h, and stained for KS virus 
at 18-24 h by immunoperoxidase.  The theoretical limit of detec- 
tion for this assay is ~  5 PFU/mouse, or 25 PFU per gram of lung 
tissue. 
~esult$ 
Phenotype of T  Cell Lines.  As in previous  studies  (17), 
splenic T cell cultures from 22K primed mice rapidly became 
dominated by CD4-8 + cells.  A  typical FACS  |  analysis on 
day 3 after the third cycle is shown in Fig.  1 C. These cells 
required added Con A  supernatant to grow. The G-specific 
line was comprised mainly of CD4+8 -  T  cells (Fig.  1 A), 
and  continued  to  grow  without  addition  of  exogenous 
cytokines.  The  F-specific  line  also  grew  without  added 
cytokines and on day 3 after the second cycle, contained 28% 
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Figure  1.  FACS  |  analysis  of G-, 
F-, and 22K-specific  cell lines. Cell 
lines from mice primed with rVV-G, 
-F, or -22K were expanded by cycles 
of antigen stimulation. Methods of 
derivation differed only in the RS 
virus protein  to  which  the  mice 
were sensitized, except that exoge- 
nous cytokines  were added to main- 
tain growth of 22K-specific cells as 
the  level of  endogenous CD4 + 
cells (and T cell help) declined in 
these cultures. Lines were stained 
with anti-CD4 coupled to GK1.5 
PE and anti-CD8  coupled to 53-6.7  FITC. In these examples, the G line (A) is 89% CD4+8 -  and 4% CD4-8 § , whereas the F line (B) is 71% 
CD4+8 -  and 26% CD4-8 § and the 22K line (C) is 5.6% CD4+8 -  and 74% CD4-8 + , with a further  19% in the CD4-8- "tail" of cells, which 
appears to be continuous  with the main CD8 § cell population. 
CD4+8 -  and 41%  CD4-8 §  cells.  At this  same time,  a G 
line was  50%  CD4+8 -  and  26%  CD4-8 §  By the  third 
cycle, their ratios had changed to 48 and 34% for F cells and 
71 and 13% for G cells, respectively. A  typical CD4/8 anal- 
ysis  of an  F  line  after  the  fourth  stimulation  is  shown  in 
Fig.  1 B. 
Functional Characteristics of Cell Lines In Vitro.  From the 
third cycle of stimulation,  cytokine production and cytotox- 
icity against  P815  (H-2K  a) target cells showed  stable char- 
acteristics. The 22K-specific line produced no detectable IL-2, 
IL-4,  or  IL-5  in  response  to  antigen,  but  supernatants  of 
antigen-stimulated  cultures  were rich in IL-3. By contrast, 
the G-specific line produced IL-5, IL-4, and IL-3 but not IL-2 
in response to antigen (Table 1).  The F-specific line released 
excess  IL-2 but  not  IL-5  (Table 2). 
In cytotoxicity assays against P815 cells,  the 22K-specific 
line showed virus- and protein-specific cytotoxicity against 
cells infected with RS virus or rVV-22K. F-specific cells lysed 
P815  cells  infected  with  KS virus  or rVV-F  (51  and  49% 
specific lysis, respectively, at killer/target ratio [K/T] 50:1), 
but  did  not  cause significant  lysis of targets  infected  with 
rVV-G (15%)  rVV-/~3al (8%)  or uninfected  targets (13%) 
to a significant degree. The G-specific line cause <15% lysis 
of any of these  targets  at  K/T  ratios  ~<50:1. 
Signs  of IUness After Cell  Transfers.  In  all  cases,  mock- 
infected mice appeared well, with stable or slightly increasing 
body weights and were not affected by cell transfers. Influenza- 
infected mice appeared mildly ill, lost 3-5% of body weight 
by day 4  but  were not  affected by cell transfers.  RS virus- 
infected  mice generally  appeared  well unless  injected  with 
T  cells. 
In experiment 1, KS virus-infected mice not injected with 
cells showed a decline in weight to 93.2  _+ 0.5% of starting 
weights by day 2, recovering thereafter to 96.4  +_ 0.5 by day 
4. By contrast, KS virus-infected mice injected with G, 22K, 
or both cell lines became rapidly unwell with lethargy, ruffled 
fur, tachypnoea, cyanosis, and progressive weight loss, which 
was most  severe among mice injected  with  both cell lines 
(83.5  _+  4.2%  of starting weight on day 4), followed by G 
recipients (87.9  _+  8%),  and was least in 22K recipients (90 
+  3.8%). 
In experiment 2, RS virus-infected mice did not lose weight 
except when injected  with  T  cells.  Those given G  or 22K 
cells alone, and those given a 1:3 or 3:1 mixture of cells lost 
Table  1.  Cytokine  Production by 22K- and G Protein-Specific T  Cell Lines 
22K line  G  line 
Without  Ag  With  Ag  Without  Ag  With  Ag 
cpm  x  10 -7 
IL-2  0.2  _+  0.02  0.16  _+  0.02  0.29  _+  0.02  0.26  __.  0.05 
IL-3  4.89  _+  1.16  14.67  _+  1.11  4.37  _+  0.79  14.5  __.  2.02 
IL-4  0.16  __  0.04  0.17  +  0.02  0.80  --  0.02  5.50  _+  0.54 
IL-5  -0.25  _+  0.04  0.013  _  0.001  0.35  -+  0.47  10.82  __.  0.59 
Production of IL-2, -3, -4, and -5 by 22K- and G protein-specific T cell lines, expressed as thousands of cpm. Background proliferation of IL-2-respon- 
sive CT.EV cells (135 _+ 38 cpm), IL-4 responsive CT.4S (84  _+  14), and IL-3/5-responsive B13 (478  +  150) cells have been subtracted. Positive 
controls for each of these cell lines (5% CS from  x 6310 cell lines producing IL-2, -4, or -5) were 11,601  _+ 213; 2,939  _+  111; and 9,477  _+ 787, 
respectively. The IL-5 readout is the inhibition of B13 [3H]TdR incorporation by anti IL-5 mAb TRFK-5, which leaves residual incorporation here 
ascribed to IL-3. The 22K line generates good levels of IL-3, but not IL-2, IL-4, or IL-5 (typical of CTL), whereas the G line generates IL-4 and 
IL-5, but not IL-2 (typical of Th2). 
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CTLL proliferation  B13 proliferation 
No  anti-IL-2  With  anti-IL-2  No  anti-IL-5  With  anti-IL-5 
cpm  x  10 -3 
F  line  5.65  +  0.6  0.41  .+  0.55  8.84  _+  0.5  8.4  _+  1.3 
G  line  3.13  .+  0.85  2.87  +  1.15  13.00  _+  1.6  4.6  _+  1.0 
Cytokine production by F and G cell lines,  expressed in thousands  of cpm. Background  proliferation  of CTLL (480 cpm) and B13 (630 cpm) cells 
was  not affected by respective  anticytokines,  and has been  subtracted.  Ab inhibition shows that  the F line generates  good levels of IL-2 but  not 
IL-5, whereas  the G line generates  IL-5 but not significant IL-2.  CS from the F line contains  IL-3,  which causes B13 cells to proliferate  regardless 
of anti-IL-5  Ab.  CS from the G line also contains  IL-3  (accounting  for nearly  one third of the total B13 proliferation)  and  IL-4,  which appears 
responsible  for most of the CTLL proliferation  (see 16  and  17 for further discussion). 
10-20% of body weight by day 4. Those given 3:3 mixtures 
(total 6  x  106 cells) lost 25.5  +  2.0%  of starting weight 
by day 4 (Fig. 2). Deaths due to the severity of augmented 
lung disease occurred between days 3 and 4 in one mouse 
given G-specific cells,  and two mice given G and 22K cells 
at a 3:1 ratio. No deaths due to lung disease occurred in other 
groups or in other experiments, although three mice failed 
to recover from anesthesia. 
In experiment 3, RS virus-infected mice maintained static 
weight unless simultaneously injected with T cells, in which 
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Figure  2.  Weight loss caused by G- and 22K-specific T cell lines in RS 
virus-infected mice. Mean group weights  +  SEM of KS virus infected 
mice in experiment 2, with or without cell transfers, calculated as percent 
of starting  weight for each mouse.  Groups  are: (l-q) R.S virus infection, 
no cells; (ll) KS virus and 3  x  106 22K cells; (')  RS virus and mixed 
cells (106 G and 3  x  106 22K); (A) KS virus and mixed cells (3  x  106 
of each); (O) RS virus and mixed cells (3  x  106 G and 106 22K); (A) 
KS virus and 3  x  106 G cells. Control groups not infected with KS virus 
(i.e., infected with influenza or mock infected) were not affected by cell 
transfers and  are not shown in the figure. 
case they became ill by day 2 after transfers.  Infected recipients 
of F-specific cells lost 6.7% and G-specific recipients 13.3% 
of starting weights by day 4. Simultaneous injection of both 
cell lines produced effects similar to G-specific cells alone up 
to day 3  (Fig.  3). 
Effects of Transfer of  Individual Cell Lines on BAL Parameters. 
In all cases,  no significant lung hemorrhage, PMN efftux, 
eosinophilia, or lymphocytosis occurred in mock-infected mice 
regardless of cell transfers. Influenza-infected mice developed 
lymphocytosis and PMN efflux, but were again unaffected 
by cell transfers (e.g., experiment 3, influenza only: 9.1  _+ 
1.1% PMN; influenza with cell transfers: 6.1 +_ 1.4% PMN, 
100 
90 
80  I  I  I  ~  I 
0  1  2  3  4 
Days 
Figure  3.  Weight loss caused by G- and F-specific T cell lines in KS 
virus-infected  mice. Mean group weights  _+  SEM of KS virus-infected 
mice, with or without cell transfers in experiment  3, calculated as percent 
starting  weight for each mouse.  Groups are: (I-q) KS virus infection,  no 
cells; (A) RS virus and 3  x  106 G cells; (ll) RS virus and 3  x  106 F 
cells; (A) KS virus and mixed cells (6  x  106 total).  Control groups not 
infected with RS virus (i.e., infected with influenza or mock infected) were 
not affected by cell transfers and  are not shown in the figure. 
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Figure  4.  Pathological effects of G- and 22K-specific cell lines. Groups 
of RS virus-infected mice: (A) left without i.v. injection; (B) injected with 
3  x  106 22K-specific cells; (C) 3  ￿  106 22K and 106 G-specific cells; (D) 
3  x  106 of each line; (E) 106 22K and 3  x  106 G-specific cells; and (F) 
3  x  106 G-specific cells. Cell transfers were done at the same time as RS 
virus infection,  either after the third (experiment  1,  r  or after the fifth 
(experiment 2, O) cycle of in vitro growth. Either cell line caused lung 
hemorrhage and PMN efflux into BAL fluid (shock lung), and the effects 
of combined cell transfers were additive in this regard. By contrast, only 
G-specific cells cause eosinophilic pneumonitis, the severity of which was 
reduced by the addition of 22K-specific cells. Neither cell line enhanced 
disease in influenza- or mock-infected  mice (data not shown, see text). 
p  =  0.2; hemorrhage: 67  •  7 #g/ml without, 70  +  5.5/~g/ 
ml with cells, p  =  NS).  RS virus-infected  mice developed 
mild pulmonary lymphocytosis as previously described (23), 
but no other pathological effects unless T cells were injected. 
T cell injections only affected disease in RS virus-infected 
mice.  In  all  experiments,  such  mice  given  G-specific  cells 
showed brisk lung hemorrhage, PMN and eosinophil eflqux. 
Those given 22K cells showed mild lung hemorrhage, occa- 
sional slight PMN efflux (5.7% in one mouse in experiment 
1,  Fig.  4),  but not  eosinophilia  (Figs.  4  and 5).  Injecting 
F-specific cells into  such mice caused slight but significant 
lung hemorrhage  (Fig.  5,  top; 29  •  3  in A  vs  109  _+  20 
/~g/ml in B, p  --  0.03, Student's t test) but no PMN or eo- 
sinophil  efflux. 
Effects of Combined Transfer  Different Cell Lines.  Equal mix- 
tures of G and 22K cells caused an increase in lung hemor- 
rhage and PMN efflux, compared with the effects of either 
cell line alone. Combining the results of experiments 1 and 
2,  addition of 3  x  106 22K  to 3  x  106 G  cells  enhanced 
PMN efflux from 26.8  _+  2  to 36.7  _+  3.7%  (F  =  0.045, 
Student's t test). By contrast, the eosinophilia seen in recipients 
of G-specific cells was reduced by coadministration of 22K 
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Pathological effects of G- and F-specific T cell lines. Groups 
of RS virus-infected  mice: (A) no i.v. injection; (B) injected with 3  x 
106 F protein-specifc T cells; (C) injected with both cell lines (6  x  106 
total); and (/9) injected with 3  x  106 attachment protein G-specific  T 
cells. On day 4, all mice were subjected to BAL for quantification of lung 
hemorrhage (BAL Hb, #g/ml, top) and differential  cell counts (e.g., PMN% 
and eosinophil%, middle and bottom). The F-specific cells caused slight hut 
significant lung hemorrhage  (29  _+  3  in A  vs 109  -+  20 #g/ml in B, 
p  =  0.03, Student's t test) but not PMN or eosinophil ef[tux. The G-specific 
cells caused severe lung hemorrhage (618  _+  72/~g/ml), eosinophil,  and 
PMN e~ux. F- and G-specific cells together caused pathological effects 
similar to G  cells alone. No additional pathological  effects were caused 
by injection of T cells into uninfected, mock-, or influenza-infected mice 
(see text). 
cells (e.g., 30.4  _+ 0.3 vs 8.3  _+  1.15%,p  =  0.003 in experi- 
ment 2). Unequal mixtures produced immediate results (Fig. 
4). Combined injections os F and G cells caused pathological 
effects  similar to G  cells  alone (Fig.  5). 
Effects of Cell Transfer on RS Virus Replication.  In experi- 
ment  1,  either  the 22K  or G  cell  line caused a significant 
~<0.05,  Student's t test) reduction in lung virus titer com- 
pared with those not given cells, whereas coinjection of both 
cell lines eliminated virus completely (Fig. 6 A).  In experi- 
ment 2, the same pattern was seen (Fig. 6 B; data from asym- 
metrical transfers not shown, but where no lung virus was 
detected).  In experiment 3, RS virus-infected mice injected 
with  F-specific cells  had greatly  reduced lung virus titers, 
whereas G-specific cells or combinations of F- and G-specific 
cells virtually eliminated virus from the lungs  (Fig.  6  C). 
Discussion 
These studies show that injection of viral protein-specific 
T cell lines into naive mice coinfected with P,S virus can re- 
duce virus replication  in the lungs, but that each also produces 
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1,000 
300 
1oo 
~  3o 
10 
|  A 
|  $ 
3'~176176  B 
1,000 l 
30 t 
10k 
3,000 
1,000 
30(2 
100 
30 
10 
t 
!  . 
i  i  i  A~_  i  A  i  i  i  i  w 
0  22K  O  22K+G  0  ZZK  O  22K+G  0  F  G  F,"G 
Figure 6.  Antiviral  effects  of in- 
jection of T cell lines. Mice were 
subjected to BAL on day 4 after  in- 
tranasal  infection  with KS virus, and 
lungs homogenized  for determina- 
tion of virus titer. The performance 
of BAL before lung virus recovery 
reduces lung virus titers (23), but 
does not invalidate  the comparisons 
shown here. Results  for individual 
mice are shown  in infectious  units 
(pfu) per mouse (y-axis). The theo- 
retical limit of detection for this 
assay is ,,o5 PFU/mouse. Results 
have not been corrected for lung weight, since acute  changes in weight result from infiltration  or fluid  and not from  changes in true pulmonary  mass. 
Such a correction would falsely  lower virus titers in inflamed  lungs that were unaffected  in their ability  to support virus replication. In experiment 
1 (A) 22K- and G-specific  cell lines were tested  by intravenous  transfer  after three cycles  in vitro stimulation, and in experiment 2 (B) after  five  cycles. 
In C, the effects  of F- and G-specific  cells are shown. No virus could  be isolated  after  coinjection  of G- and 22K-specific  cells, either  with equal numbers 
(i.e., 3  x  106 of each, 22K+G  or F+G) or unequal numbers (i.e., ratios of 3:1 or 1:3) of cells (data not shown). 
a  characteristic pattern  of disease  enhancement.  The  im- 
munopathology in mice given specific T cells largely repro- 
duces that seen in mice sensitized to the KS virus protein 
which the ceils recognize, and correlates with the phenotypic 
and functional properties of the T  cell lines  in vitro. 
First, KS virus-infected mice injected with T  cells from 
mice primed with rVV-F develop mild disease augmentation 
of a similar pattern to that seen in mice sensitized by rVV-F 
infection (15). This recombinant induces strong RS virus- 
specific CTL (24) and Th cell (25) responses. The T cell line 
contained both CD4 + cells (which produced IL-2 but not 
IL-5) and CD8 + CTL. 
Second, priming with rVV-22K (which expresses the prin- 
cipal target for Ka-restricted CTL and induces CTL in vivo 
[19]) leads to a cell line that is almost exclusively CD8 + , has 
CTL (but not Th) activity, and induces more marked disease 
augmentation, with lung hemorrhage PMN efl:lux. This pat- 
tern of disease may be caused by CTL recognition of infected 
pulmonary epithelial cells, thereby resulting in a breakdown 
of the alveolar/capillary  membrane. 
Third, the G-specific cell line induces a more severe and 
quite distinct pattern of disease with severe eosinophilic pneu- 
monitis similar to that seen in RS virus-infected mice sensi- 
tized with rVV-G (15). In vitro, the G-specific line releases 
IL-3, IL-4, and IL-5, but little IL-2. On the basis of results 
obtained from Th cell clones,  Street et al.  (26) and others 
have proposed that Th cells can be divided into Thl (producing 
IFN-3', IL-2, and IL-3) and Th2 (producing IL-3, IL-4, and 
IL-5, among other factors). One explanation for the present 
results is that the KS virus-specific Th cells induced by rW-G 
are predominantly Th2 cells which produce cytokines that 
induce the differentiation, maturation, migration, prolifera- 
tion, and survival  of eosinophils. In murine leishmaniasis, 
cells that behave as Thl cells protect against infection, whereas 
those that exhibit Th2  properties  enhance DTH and the 
severity of the disease and are associated with chronicity (27, 
28). These Th subsets may also be relevant to in vivo responses 
to other infectious agents such as schistosomulae (29), listeria 
(30),  and Brucella  abortus  and Nippostrongylus  (26),  but the 
studies described herein are the first to indicate that such Th 
subsets might also explain pathological responses to viral in- 
fections. 
These findings are largely consistent with our previous 
studies,  in which polyclonal KS virus-specific T  cell lines 
were separated into CD4 + and CD8 + T cell-enriched frac- 
tions  by  immunomagnetic adhesion.  Transfer  of CD4 § 
CD8 .+, or both cell fractions caused KS virus-infected mice 
to become ill and lose weight, whereas infection alone caused 
no overt illness. Either fraction also caused an increase in the 
severity of lung pathology (as monitored by BAL) with the 
appearance  of lung hemorrhage and PMN efflux. In addi- 
tion,  recipients  of CD4 §  ceils  developed  pulmonary eo- 
sinophilia. There is some evidence  from these studies  that 
coinjection of CD4 § and CD8 § cells may reduce the sever- 
ity of pathology, compared with the effects of either subset 
alone (9). In these studies, mice given both G and 22K lines 
showed enhanced PMN efflux and reduced eosinophilia com- 
pared with those given 22K or G cells alone. F-specific cells 
alone caused minimal enhancement of disease, and did not 
much influence the disease caused by G-specific cells either 
in terms of weight loss or lung pathology. They did, how- 
ever, exhibit antiviral effects. 
In other experimental situations, sequential actions of CD8 
and CD4 subsets may be required for antiviral DTH responses 
(31), and cooperation of both subsets may be required to pro- 
tect against infection (32). Different subsets may have different 
roles at different sites (33, 34), and in different genetic strains 
of animal. For example, protective T cells that recognize the 
nucleoprotein of vesicular stomatitis virus are CD4 § in H-2  k 
mice, but CD8 § in H-2  b strains  (35). 
Although these studies highlight the potentially patho- 
genic role of Th cells that recognize the attachment protein 
G, they should not be taken to indicate that all subunit or 
recombinant vaccines containing G  will be pathogenic, or 
that the same applies to other strains of mice or to other 
species. Mice seem to be more prone to pathogenic responses 
than cotton rats (10), and BALB/c mice may be particularly 
susceptible to eosinophilia (36) and perhaps to the development 
of CTL-induced immunopathology (37),  thereby making 
them the best available model in which to define mechanisms 
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timing and strength of the T cell response. These studies show 
what can happen if highly activated T  cells are present at 
the start of infection. A less exuberant T cell response would 
be less likely to be pathogenic, and is probably an essential 
component of the protective immune response to any effec- 
tive vaccine. 
In addition to possible  implications for vaccine develop- 
ment, the appearance  of eosinophils in the lungs of sensi- 
tized RS virus-infected mice may be relevant  to the patho- 
genesis of asthma in humans. Eosinophilia in the lung and 
blood is a frequent finding in asthmatics, in whom the bron- 
chial epithelium is infiltrated with Th2-1ike lymphocytes (38). 
Wheezing is an important clinical sign ofbronchiolitis, and 
respiratory viral infections are common precipitants of attacks 
of asthma (39, 40). Children with a history of bronchiolitis 
often suffer respiratory symptoms typical of asthma in later 
childhood (41, 42) and respiratory morbidity in adult life may 
also be affected  (43).  The mechanisms by which viral in- 
fections might cause delayed effects recently have been re- 
viewed (44). 
In conclusion, different components of the immunopatho- 
logical response  to RS virus infection are associated with T 
cell recognition of particular viral proteins. A vaccine that 
induced moderate, balanced T cell responses and high levels 
of neutralizing, fusion-inhibiting Ab at the mucosal surface 
would appear ideal. Further studies of the immune and patho- 
logical responses to modified recombinant proteins may show 
how protective immunity can be induced without causing 
harmful reactions to subsequent RS virus infections. 
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